NU 578 UNIT 4 EXAM | QUESTIONS AND
ANSWERS | 2026 UPDATE | 100% CORRECT –
USA ACTUAL REAL EXAM ACCURATE
QUESTIONS AND ANSWERS WITH RATIONALES
| VERIFIED AND LATEST UPDATED |
GUARANTEED PASS
Question 1:
Which of the following is a uricosuric agent for the treatment of gout?
A. Colchicine (Colbenemid)
B. Probenecid (Benemid)
C. Methylprednisolone
D. Allopurinol (Zyloprim)
Correct Answer: B. Probenecid (Benemid)
Rationale: Probenecid is a uricosuric agent that increases uric acid excretion by
inhibiting the reabsorption of uric acid in the renal proximal tubules. It is used for
chronic gout in patients with normal renal function and underexcretion of uric acid.
It is contraindicated in patients with overproduction of uric acid, renal
insufficiency, or history of uric acid stones.
Question 2:
What is the mechanism of action of allopurinol (Zyloprim)?
A. Uricosuric agent increasing uric acid excretion
B. Xanthine oxidase inhibitor decreasing uric acid production
C. Anti-inflammatory agent reducing urate crystal inflammation
D. IL-1 inhibitor blocking inflammatory cascade
Correct Answer: B. Xanthine oxidase inhibitor decreasing uric acid production
Rationale: Allopurinol is a xanthine oxidase inhibitor that reduces uric acid
production by inhibiting the conversion of hypoxanthine to xanthine and xanthine
to uric acid. It is used for chronic gout, particularly in patients with overproduction
,of uric acid, tophaceous gout, and uric acid nephropathy. Dosing should be
adjusted for renal function.
Question 3:
A patient with acute gout attack presents with severe joint pain. Which medication
is most appropriate for acute management?
A. Allopurinol
B. Probenecid
C. Colchicine
D. Febuxostat
Correct Answer: C. Colchicine
Rationale: Colchicine is used for acute gout flares due to its anti-inflammatory
effects by binding to tubulin and inhibiting microtubule polymerization, reducing
neutrophil chemotaxis and inflammatory cytokine release. It is most effective when
started within the first 24 hours of the attack. The dose is 1.2 mg followed by 0.6
mg one hour later, with monitoring for GI side effects.
Question 4:
Which medication used for gout requires dose adjustment in patients with renal
impairment?
A. Colchicine
B. Probenecid
C. Allopurinol
D. Indomethacin
Correct Answer: C. Allopurinol
Rationale: Allopurinol and its active metabolite oxypurinol are renally excreted,
requiring dose adjustment based on creatinine clearance to prevent toxicity (rash,
Stevens-Johnson syndrome, bone marrow suppression). The starting dose in renal
impairment is typically 100 mg daily, with gradual titration. Febuxostat may be
preferred in patients with renal impairment.
,Question 5:
What is the recommended prophylactic treatment for gout flares when initiating
urate-lowering therapy?
A. Probenecid
B. Colchicine or NSAID
C. Allopurinol only
D. Corticosteroids
Correct Answer: B. Colchicine or NSAID
Rationale: When starting urate-lowering therapy (allopurinol, febuxostat), gout
flares often occur due to rapid changes in serum uric acid and mobilization of urate
crystals. Prophylaxis with low-dose colchicine (0.6 mg daily) or an NSAID
(naproxen 250 mg BID) is recommended for 3-6 months to reduce flare frequency
while achieving target uric acid levels.
Question 6:
Which xanthine oxidase inhibitor is preferred in patients with renal impairment?
A. Allopurinol
B. Probenecid
C. Febuxostat (Uloric)
D. Colchicine
Correct Answer: C. Febuxostat (Uloric)
Rationale: Febuxostat is primarily metabolized by the liver and can be used in
patients with mild-to-moderate renal impairment without dose adjustment. It is
more potent than allopurinol at lowering uric acid. However, it carries a black box
warning for increased cardiovascular mortality and should be used cautiously in
patients with cardiovascular disease.
Question 7:
Which medication for gout is a selective IL-1β inhibitor?
A. Canakinumab (Ilaris)
B. Rilonacept
, C. Anakinra
D. All options are correct
Correct Answer: D. All options are correct
Rationale: All three medications (canakinumab, rilonacept, anakinra) are IL-1
inhibitors used off-label for refractory gout flares when traditional therapies are
contraindicated or ineffective. Canakinumab is the only FDA-approved IL-1
inhibitor for gout flares, given as a single subcutaneous injection. These agents
block the inflammatory cascade triggered by urate crystals activating the NLRP3
inflammasome.
Question 8:
What is the target serum uric acid level for gout treatment?
A. < 8 mg/dL
B. < 7 mg/dL
C. < 6 mg/dL
D. < 5 mg/dL
Correct Answer: C. < 6 mg/dL
Rationale: The treatment target for gout is serum uric acid < 6 mg/dL, which
promotes dissolution of urate crystals and reduces gout flares. In patients with
tophi, a lower target of < 5 mg/dL may be recommended to accelerate tophus
regression. Achieving target reduces the frequency of acute attacks and prevents
joint damage and tophi formation.
Question 9:
Which dietary modification is recommended for patients with gout?
A. Increased purine-rich foods
B. Reduced alcohol intake (especially beer)
C. Increased high-fructose corn syrup
D. Reduced fluid intake
Correct Answer: B. Reduced alcohol intake (especially beer)
ANSWERS | 2026 UPDATE | 100% CORRECT –
USA ACTUAL REAL EXAM ACCURATE
QUESTIONS AND ANSWERS WITH RATIONALES
| VERIFIED AND LATEST UPDATED |
GUARANTEED PASS
Question 1:
Which of the following is a uricosuric agent for the treatment of gout?
A. Colchicine (Colbenemid)
B. Probenecid (Benemid)
C. Methylprednisolone
D. Allopurinol (Zyloprim)
Correct Answer: B. Probenecid (Benemid)
Rationale: Probenecid is a uricosuric agent that increases uric acid excretion by
inhibiting the reabsorption of uric acid in the renal proximal tubules. It is used for
chronic gout in patients with normal renal function and underexcretion of uric acid.
It is contraindicated in patients with overproduction of uric acid, renal
insufficiency, or history of uric acid stones.
Question 2:
What is the mechanism of action of allopurinol (Zyloprim)?
A. Uricosuric agent increasing uric acid excretion
B. Xanthine oxidase inhibitor decreasing uric acid production
C. Anti-inflammatory agent reducing urate crystal inflammation
D. IL-1 inhibitor blocking inflammatory cascade
Correct Answer: B. Xanthine oxidase inhibitor decreasing uric acid production
Rationale: Allopurinol is a xanthine oxidase inhibitor that reduces uric acid
production by inhibiting the conversion of hypoxanthine to xanthine and xanthine
to uric acid. It is used for chronic gout, particularly in patients with overproduction
,of uric acid, tophaceous gout, and uric acid nephropathy. Dosing should be
adjusted for renal function.
Question 3:
A patient with acute gout attack presents with severe joint pain. Which medication
is most appropriate for acute management?
A. Allopurinol
B. Probenecid
C. Colchicine
D. Febuxostat
Correct Answer: C. Colchicine
Rationale: Colchicine is used for acute gout flares due to its anti-inflammatory
effects by binding to tubulin and inhibiting microtubule polymerization, reducing
neutrophil chemotaxis and inflammatory cytokine release. It is most effective when
started within the first 24 hours of the attack. The dose is 1.2 mg followed by 0.6
mg one hour later, with monitoring for GI side effects.
Question 4:
Which medication used for gout requires dose adjustment in patients with renal
impairment?
A. Colchicine
B. Probenecid
C. Allopurinol
D. Indomethacin
Correct Answer: C. Allopurinol
Rationale: Allopurinol and its active metabolite oxypurinol are renally excreted,
requiring dose adjustment based on creatinine clearance to prevent toxicity (rash,
Stevens-Johnson syndrome, bone marrow suppression). The starting dose in renal
impairment is typically 100 mg daily, with gradual titration. Febuxostat may be
preferred in patients with renal impairment.
,Question 5:
What is the recommended prophylactic treatment for gout flares when initiating
urate-lowering therapy?
A. Probenecid
B. Colchicine or NSAID
C. Allopurinol only
D. Corticosteroids
Correct Answer: B. Colchicine or NSAID
Rationale: When starting urate-lowering therapy (allopurinol, febuxostat), gout
flares often occur due to rapid changes in serum uric acid and mobilization of urate
crystals. Prophylaxis with low-dose colchicine (0.6 mg daily) or an NSAID
(naproxen 250 mg BID) is recommended for 3-6 months to reduce flare frequency
while achieving target uric acid levels.
Question 6:
Which xanthine oxidase inhibitor is preferred in patients with renal impairment?
A. Allopurinol
B. Probenecid
C. Febuxostat (Uloric)
D. Colchicine
Correct Answer: C. Febuxostat (Uloric)
Rationale: Febuxostat is primarily metabolized by the liver and can be used in
patients with mild-to-moderate renal impairment without dose adjustment. It is
more potent than allopurinol at lowering uric acid. However, it carries a black box
warning for increased cardiovascular mortality and should be used cautiously in
patients with cardiovascular disease.
Question 7:
Which medication for gout is a selective IL-1β inhibitor?
A. Canakinumab (Ilaris)
B. Rilonacept
, C. Anakinra
D. All options are correct
Correct Answer: D. All options are correct
Rationale: All three medications (canakinumab, rilonacept, anakinra) are IL-1
inhibitors used off-label for refractory gout flares when traditional therapies are
contraindicated or ineffective. Canakinumab is the only FDA-approved IL-1
inhibitor for gout flares, given as a single subcutaneous injection. These agents
block the inflammatory cascade triggered by urate crystals activating the NLRP3
inflammasome.
Question 8:
What is the target serum uric acid level for gout treatment?
A. < 8 mg/dL
B. < 7 mg/dL
C. < 6 mg/dL
D. < 5 mg/dL
Correct Answer: C. < 6 mg/dL
Rationale: The treatment target for gout is serum uric acid < 6 mg/dL, which
promotes dissolution of urate crystals and reduces gout flares. In patients with
tophi, a lower target of < 5 mg/dL may be recommended to accelerate tophus
regression. Achieving target reduces the frequency of acute attacks and prevents
joint damage and tophi formation.
Question 9:
Which dietary modification is recommended for patients with gout?
A. Increased purine-rich foods
B. Reduced alcohol intake (especially beer)
C. Increased high-fructose corn syrup
D. Reduced fluid intake
Correct Answer: B. Reduced alcohol intake (especially beer)
